Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entrada Therapeutics Inc.

www.entradatx.com

Latest From Entrada Therapeutics Inc.

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Financing StartUps and SMEs

Venture Funding Deals: Relay Closes Out 2018 With $400m Series C

2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more... 

Deals Financing

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Entrada Therapeutics Inc.
  • Senior Management
  • Dipal Doshi, President & CEO
    Natarajan Sethuraman, PhD, CSO
    Mario Saltarelli, MD, PhD, CMO
    Nathan J Dowden, COO
  • Contact Info
  • Entrada Therapeutics Inc.
    28 State Street
    Suite 2303
    Boston, MA 02109
    USA
UsernamePublicRestriction

Register